Bayer to cut 227 positions in California to drive efficiency in haemophilia

pharmafile | October 4, 2018 | News story | Manufacturing and Production Bayer, haemophilia, pharma 

Bayer has announced its intention to axe 227 employees at a manufacturing site in California as part of a push to drive greater operational efficiencies in its haemophilia business.

Half of the total layoffs will come into effect immediately. Bayer has said that the cuts will have no effect on access for patients to its treatments. The company be left with around 1,100 staff in total after the planned departures.

The move is thought to come in response to pressure within the haemophilia space, as sales of two of its three recombinant factor VIII therapies were impacted by a planned termination agreement with a distribution partner, dropping 20% to €427 million from the previous year.

“The manufacturing processes for these products must […] be robust and efficient to ensure product safety, reliable supply, and to remain competitive in support of new therapies that position the long term viability of the site,” the company said in a statement. “Our transition into commercial production with three products has resulted in the need for organisational changes to enable these efficiencies, and today we notified 227 employees that their positions were being eliminated as part of this reorganisation.

Advertisement

“We have the utmost appreciation for the employees affected by this reorganisation, and will ensure that we manage their transition in the most respectful and thoughtful manner that we can.”

Matt Fellows

Related Content

Evotec and Bayer announce new kidney disease study

Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

blood-1813410_960_720

Novo Nordisk presents promising findings for haemophilia treatment

Novo Nordisk has presented data indicating that a direct switch to Mim8 (denecimig) prophylaxis treatment …

The Gateway to Local Adoption Series

Latest content